USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Shenzhen Mindray Bio-medical Electronics Co., Ltd.

USPTO PatentsView assignee record - 391 granted patents across 73 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61B (DIAGNOSIS; SURGERY; Identification).

RSS updates for this company

The verdict

According to USPTO PatentsView, Shenzhen ranks #1,089 of 49,997 tracked US assignees by granted-patent volume, with 391 patents across 73 technology areas.

#1,089
of 49,997 US assignees by volume
Top 1%
by Innovation Score (66.3/100)
16.5
avg claims per patent
+73%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R1089 · Foreign Corporation #1,089 · 391 grants

GRANTS-MID · TOP-DECILE · PHOTO-FINISH · CPC-WIDE · INNOV-STRONG · CLAIMS-RICH · TYPE-FRNCORP · VEL-SURGE · BOOK-FULL

  • GRANTS-MID 391 grants
  • TOP-DECILE #1,089/49,997
  • PHOTO-FINISH Oxford University…
  • CPC-WIDE A61B · 73 areas
  • INNOV-STRONG 66.3/100
  • CLAIMS-RICH 16.5 claims/avg
  • TYPE-FRNCORP Foreign Corp
  • VEL-SURGE +73% vel
  • BOOK-FULL 10/10 fields

Nearest grant-volume peer: Oxford University Innovation Limited (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Innovation-score neighbourhood around Shenzhen

Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.

score

What this shows Shenzhen's Innovation Score is 66.3/100 (top 1% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Source USPTO PatentsView, PlainPatent Innovation Score As of 2015–2025

How Shenzhen's grant cadence moved

Between 2020–2024, Shenzhen Mindray Bio-medical Electronics Co., Ltd. received 227 grants versus 131 in 2015–2019 (+73% equal-window velocity, above median growth). Across complete PatentsView years, output peaked in 2024 at 58 grants and bottomed in 2016 at 21. Lead class A61B accounts for 58.8% of the portfolio across 73 subclasses. Volume neighbours: CommScope Connectivity Belgium Bvba (#1,085) and Allison Transmission, Inc. (#1,093).

Shenzhen's three-year grant acceleration

From 2019–2021 to 2022–2024, Shenzhen Mindray Bio-medical Electronics Co., Ltd. moved from 95 to 154 grants (1.62x the prior three-year total, a multiple, not a CAGR). Among 3,296 tracked assignees with ≥100 grants and ≥20 prior-period grants, that multiple ranks #361. See the growth leaderboard.

Who files at Shenzhen's volume?

Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀

patents

What this shows Shenzhen holds 391 patents at rank #1,089, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Source USPTO PatentsView, granted utility patents As of 2015–2025

Companies ranked near Shenzhen

By rank, the assignees closest to #1,089 in granted patent volume.

Leaders in A61B (Diagnosis)

Other assignees with the most granted patents in Shenzhen's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Shenzhen, neither rank-band nor same-CPC leaders (those blocks stay above).

Shenzhen's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

66 Top 1% higher than 99% of 49,997 US assignees

This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

102030405060 20152016201720182019202020212022202320242025 33
USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table
Shenzhen Mindray Bio-medical Electronics Co., Ltd. patent grants by year, 2015–2025
Year Patents Granted Share of Period
2015 38 9.7%
2016 21 5.4%
2017 26 6.6%
2018 24 6.1%
2019 22 5.6%
2020 36 9.2%
2021 37 9.5%
2022 43 11.0%
2023 53 13.6%
2024 58 14.8%
2025partial year 33 8.4%

Which technologies does Shenzhen Mindray Bio-medical Electronics Co., Ltd. patent most?

Top 15 of 73 technology areas

Where it ranks

Overall rank by patents

#1,089

of 49,997 tracked assignees

Innovation Score

66.3 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

What to do with this data

Shenzhen Mindray Bio-medical Electronics Co., Ltd.'s patent record in context - here's where to go next.

  • Shenzhen Mindray Bio-medical Electronics Co., Ltd.'s lead technology class is A61B (DIAGNOSIS; SURGERY; Identification), 58.8% of its portfolio - see every assignee active in that class. Explore A61B
  • Ranked #1,089 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
  • Compare Shenzhen Mindray Bio-medical Electronics Co., Ltd. against CommScope Connectivity Belgium Bvba, an assignee filing at a similar volume. Compare portfolios
  • Innovation Score of 66.3/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.